A phase II study of carboplatin and cisplatin in advanced ovarian cancer.

@article{Segelov1994API,
  title={A phase II study of carboplatin and cisplatin in advanced ovarian cancer.},
  author={Eva Segelov and Robin C. Stuart-Harris and David Bell and Martin Tattersall and Jane Hutton-Potts and M E Friedlander},
  journal={European journal of gynaecological oncology},
  year={1994},
  volume={15 4},
  pages={277-82}
}
In view of the single agent activity of both cisplatin and carboplatin in epithelial ovarian cancer, and their different toxicity profiles, we carried out a phase II study of low dose cisplatin (50 mg/m2) in combination with moderate dose carboplatin (300 mg/m2) in patients with advanced ovarian cancer. Fourteen patients, all of whom had bulky disease and over half of whom had Stage IV disease, were eligible for assessment of response and toxicity. An overall response rate of 71% was… CONTINUE READING